Adjuvance Technologies, a biopharmaceutical company based at Nebraska Innovation Campus, has received a contract from the government to work on improving the influenza vaccine.
Adjuvance said it received a contract worth more than $500,000 from the National Institute of Allergic and Infectious Diseases to apply its proprietary technology in vaccine adjuvant design and manufacturing to attempt to improve the influenza vaccine. The funding will support laboratory research and animal studies. Full Story>>
By: Matt Olberding, Lincoln Journal Star